Solid Biosciences reports positive data from gene therapy trials, plans FDA meetings for accelerated approval

From GlobeNewswire: 2025-03-06 16:16:15

Solid Biosciences Inc. reported positive data from the INSPIRE DUCHENNE trial for their Duchenne gene therapy candidate, SGT-003. They plan to request FDA meeting for accelerated approval pathways. Additionally, they received FDA clearance for a clinical study of SGT-212 to treat Friedreich’s ataxia (FA). IND for SGT-501 is on track for submission in the first half of 2025. The company ended 2024 with $148.9 million in cash and $200 million from a recent offering, providing cash runway into 2027. The company aims to advance their gene therapy programs for neuromuscular and cardiac diseases.



Read more at GlobeNewswire: Solid Biosciences Reports Fourth Quarter and Full Year 2024